霉酚酸治疗肾外系统性红斑狼疮的治疗药物监测临床意义:系统综述与荟萃分析
该系统综述与荟萃分析纳入24项研究,评估霉酚酸(MPA)血药浓度与系统性红斑狼疮(SLE)临床应答的关系。结果显示MPA AUC0-12≥30-35 mg hr/L或谷浓度≥1.5 mg/L时,总体SLE应答几率高12倍,肾外表现者高15倍;但AUC0-12>60 mg hr/L或谷浓度≥2.5-3 mg/L时个别研究提示安全性担忧。
要点
- MPA AUC0-12≥30-35 mg hr/L或谷浓度≥1.5 mg/L与SLE临床应答显著相关。
- 肾外表现SLE患者在上述阈值下应答几率高15倍(95%CI 4.74-46.89)。
- AUC0-12>60 mg hr/L或谷浓度≥2.5-3 mg/L时个别研究提示安全性担忧。
核心结论
- 治疗药物监测(TDM)有助于指导MPA剂量,在SLE患者(包括肾外表现者)中平衡疗效与安全性。
研究设计与样本
- 系统综述与荟萃分析,检索评估MPA血药浓度与SLE临床应答关系的研究,最终纳入24项研究。
主要发现
- MPA AUC0-12≥30-35 mg hr/L或谷浓度≥1.5 mg/L时,总体SLE临床应答的合并OR为12倍(95%CI 5.44-27.35;P<0.0001;I2=41%)。
- 肾外表现SLE患者在上述阈值下临床应答的合并OR为15倍(95%CI 4.74-46.89;P<0.0001;I2=61%)。
- 总体SLE应答者MPA水平高32单位(95%CI 17.35-45.67),肾外表现应答者高39单位(95%CI 15.05-62.53)。
- 合并分析未显示不良事件显著增加,但个别研究提示MPA AUC0-12>60 mg hr/L或谷浓度≥2.5-3 mg/L时存在安全性担忧。
关键数值与推荐
- 临床应答相关阈值:MPA AUC0-12≥30-35 mg hr/L或谷浓度≥1.5 mg/L。
- 安全性担忧阈值:MPA AUC0-12>60 mg hr/L或谷浓度≥2.5-3 mg/L(基于个别研究)。
临床怎么用
- 对SLE患者(含肾外表现者)可考虑监测MPA AUC0-12或谷浓度,以指导剂量调整。
- 目标浓度可参考AUC0-12 30-35 mg hr/L或谷浓度1.5 mg/L以上,同时警惕AUC0-12>60 mg hr/L或谷浓度≥2.5-3 mg/L的安全性风险。
局限性
- 合并分析未显示不良事件显著增加,安全性担忧仅来自个别研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clinical response to mycophenolic acid (MPA) is highly heterogeneous; thus, therapeutic drug level monitoring (TDM) may help improve treatment efficacy. This systematic review and meta-analysis examined therapeutic ranges for MPA levels associated with better outcomes and safety in patients with systemic lupus erythematosus (SLE), particularly those with extrarenal manifestations. METHODS: We performed a comprehensive search of studies evaluating associations between MPA levels and clinical SLE response. Using forest plots, we calculated pooled odds of clinical response by MPA levels and measured the weighted mean differences across outcomes. Analysis was performed in all patients with SLE and separately in patients with extrarenal manifestations. RESULTS: Among 459 reviewed abstracts, 24 met inclusion. Summarized evidence supported that clinical response was observed at MPA area under the curve at 0 to 12 hours (AUC0-12) ≥30 to 35 mg hr/L or trough concentration (Ctrough) ≥1.5 mg/L. At these thresholds, therapeutic MPA levels were associated with 12-fold higher odds (95% confidence interval [CI] 5.44-27.35; P < 0.0001; I2 = 41%) of overall clinical SLE response and 15-fold higher odds (95% CI 4.74-46.89; P < 0.0001; I2 = 61%) of response in patients with extrarenal manifestations. Additionally, MPA levels were 32 units higher (95% CIs 17.35-45.67) in overall responders with SLE and 39 units (95% CI 15.05-62.53) higher in patients with extrarenal manifestations. Although pooled analysis did not show a significant increase in adverse events, individual studies suggested safety concerns at MPA AUC0-12 >60 mg hr/L or Ctrough ≥2.5 to 3 mg/L CONCLUSION: This study highlights the clinical utility of TDM to guide MPA dosing to balance efficacy versus safety in all patients with SLE, including those with extrarenal manifestations.
引用
- Qamhieh Z, Sriwi D, Saric C, et al. Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extrarenal Systemic Lupus Erythematosus-A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2026. PMID: 41801058. doi:10.1002/acr.80035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。